Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis
Journal of thoracic disease, Volume 7, Issue 3, 2015, Pages 455-461.
anti-programmed cell death-1 (anti-pd-1)anti-programmed cell death-ligand 1 (anti-pd-l1)non-small cell lung cancer (nsclc)
Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway has been proved one of the most promising immunotherapeutic strategies against cancer. Several antibodies have been developed to either block the PD-1 or its ligand PD-L1 are under development. So far, a series of phase I trials on PD-1/PD-L1...More
Full Text (Upload PDF)
PPT (Upload PPT)